Date:3/24/2011

" "should," "expects," "anticipates," "intends," "plans," "believes," "may," "estimates," "predicts," "projects," or similar expressions intended to identify forward-looking statements. These statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: our history of operating losses; our ability to transition into a commercial organization and generate sufficient revenue to sustain our business; our estimates of future performance, including the expected timing of the launch of our products; our ability to conduct the clinical studies required for regulatory clearance or approval and to demonstrate the clinical benefits and cost-effectiveness to support commercial acceptance of our products; the timing, costs and other limitations involved in obtaining regulatory clearance or approval for any of our product candidates; the potential benefits of our product candidates over current medical practices or other diagnostics; our ability to successfully develop, receive regulatory clearance or approval, commercialize and achieve market acceptance for any of our products and product candidates; willingness of third-party payors to reimburse for the cost of our tests at prices that allow us to generate sufficient profit margins; our reliance on third parties, including our ability to enter into collaboration agreements with respect to our product candidates and the performance of our collaborative partners under such agreements; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the expected timing, progress or success of our research and development and commercialization efforts; our
'/>"/>

SOURCE HDL, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Disease Control App for Doctors Wins Health 2.0 Data Challenge, Analyze This!
2. Coinstar to Invest in SoloHealth
3. First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU
4. Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test
5. Unhealthy Homes Pose Real Danger to Millions of Families
6. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
7. Netsmart Technologies CMHC/MIS Behavioral Health Software Passes ARRA Certification Tests
8. Pathology Lab Builds Business Success with Billing Support from Orion HealthCorp
9. M-3 Information, a Leader in Expert Behavioral Health Solutions, Launches M3Clinician.com
10. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
11. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference